王述莲,呼建民,何光伦,王成彬.肿瘤患者外周血中性粒细胞/淋巴细胞比值的研究进展[J].现代生物医学进展英文版,2017,17(34):6777-6780. |
肿瘤患者外周血中性粒细胞/淋巴细胞比值的研究进展 |
Advances in the Study of Neutrophil / Lymphocyte Ratio in Peripheral Blood of Patients with Cancer |
Received:December 28, 2016 Revised:January 24, 2017 |
DOI:10.13241/j.cnki.pmb.2017.34.039 |
中文关键词: 中性粒细胞与淋巴细胞比值 肿瘤 免疫 炎症 诊断 预后 |
英文关键词: NLR Tumor Immune Inflammation Diagnose Prognosis |
基金项目:北京市科技计划基金项目(z151100007859134) |
|
Hits: 59 |
Download times: 43 |
中文摘要: |
摘要:免疫评价指标中性粒细胞与淋巴细胞的比值(NLR)被发现和许多肿瘤的病理特征有关联 。NLR由于其便于检测、可重复性以及低廉的检测价格而受到研究者的关注。许多研究显示实体肿瘤中如乳腺癌、结直肠癌、肺癌、胃癌等的高的NLR和高的致死率或者高复发率有着联系。因此,研究NLR在肿瘤患者的诊断、治疗、预后中的作用就显得尤为重要。其机制可能与中性粒细胞对肿瘤的促进作用与淋巴细胞的肿瘤抑制作用有关。且NLR与其他炎症指标如血小板计数(Platelet count)、格拉斯哥预后评分(Glasgow Prognostic Score ,GPS)以及肿瘤标志物癌胚抗原CEA(carcino-embryonic antigen CEA)、甲胎蛋白AFP(α-fetoprotein,αFP或AFP)等可以对癌症的预后进行联合预测。而NLR作为一种新兴的检测指标同样也存在着不足与缺陷。本文就NLR对各个系统中的肿瘤的临床应用与其他诊断指标的关系的研究进展进行综述。 |
英文摘要: |
ABSTRACT: Neutrolphil to lymphocyte ratio(NLR)has been found to be associated with clinic pathological characteristics of many tumors as Immune evaluation index.NLR is concered by researchers for its easy to detect, repeatable, and cheap price. Many studies about breast cancer, colorectal cancer, lung cancer, gastric cancer have revealed the relationship between highly recurrence rate or death rate and NLR. So the study on NLR has great value in diagnose, treatment and prognosis of tumor patient. The mechanism may be related to the promoting effect of neutrophils on tumor and the tumor inhibition of lymphocytes. And the NLR and other inflammatory indexes such as platelet count (Platelet count), Glasgow outcome score (Glasgow Prognostic, Score, GPS) and carcinoembryonic antigen CEA (carcino-embryonic antigen CEA), AFP (alpha fetoprotein alpha -fetoprotein, FP or AFP) can be combined for cancer prognosis prediction. As a new indicator, NLR also has shortcomings and deficiencies. This article reviews the applications of NLR in tumors of different systems and the relationship with other diagnose index. |
View Full Text
View/Add Comment Download reader |
Close |